4D Molecular Therapeutics, Inc. - Laporan Laba Rugi (TTM)

4D Molecular Therapeutics, Inc.
US ˙ NasdaqGS ˙ US35104E1001

Laporan Laba Rugi (TTM)

Laporan Laba Rugi 4D Molecular Therapeutics, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 17 14 12 23 17 18 17 3 2 3 2 2 22 21 20 20 0 0 0 0
Change (%) -18.09 -11.28 90.64 -26.30 6.30 -4.33 -83.54 -30.49 58.51 -29.43 3.49 862.32 -5.76 -1.30 -1.15 -99.92 117.65 -37.84 43.48
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 53 53 53 52 56 61 68 73 76 80 83 86 93 97 103 111 124 141 154 170
Change (%) 0.47 -0.73 -0.94 8.22 8.72 10.78 7.67 4.23 5.21 3.78 3.78 7.09 4.89 5.62 8.06 12.11 13.73 9.08 10.44
% of Revenue 317.66 389.64 435.94 226.51 332.59 340.17 393.88 2,577.01 3,864.29 2,564.81 3,771.92 3,782.76 420.97 468.54 501.41 548.13 730,823.53 381,889.19 670,121.74 515,824.24
Gross Operating Profit -36 -39 -41 -29 -39 -43 -51 -70 -74 -77 -81 -84 -71 -76 -82 -91 -124 -141 -154 -170
Change (%) 8.99 2.91 -28.21 35.50 9.76 17.07 38.71 5.63 3.79 5.12 3.79 -16.13 8.21 7.50 10.36 37.11 13.72 9.09 10.44
% of Revenue -217.66 -289.64 -335.94 -126.51 -232.59 -240.17 -293.88 -2,477.01 -3,764.29 -2,464.81 -3,671.92 -3,682.76 -320.97 -368.54 -401.41 -448.13 -730,723.53 -381,789.19 -670,021.74 -515,724.24
SG&A 16 17 19 23 28 28 31 32 32 33 33 33 34 36 39 41 44 47 49 50
Change (%) 5.39 10.96 20.34 19.57 1.77 9.59 3.90 -0.40 3.59 -0.72 1.94 3.16 6.22 6.31 4.69 8.71 5.49 5.67 1.86
% of Revenue 98.42 126.64 158.38 99.97 162.20 155.29 177.89 1,123.10 1,609.37 1,051.71 1,479.62 1,457.51 156.24 176.10 189.68 200.89 259,723.53 125,889.19 214,004.35 151,930.30
R&D
Change (%)
% of Revenue
OpEx 69 70 72 75 84 89 99 105 108 113 116 120 127 134 141 151 168 188 203 220
Change (%) 1.63 2.13 4.73 11.69 6.44 10.40 6.50 2.82 4.73 2.47 3.27 6.00 5.25 5.81 7.14 11.20 11.57 8.23 8.36
% of Revenue 416.08 516.28 594.32 326.49 494.78 495.46 571.77 3,700.11 5,473.66 3,616.52 5,251.54 5,240.26 577.22 644.65 691.10 749.02 990,547.06 507,778.38 884,126.09 667,754.55
Operating Income -53 -57 -60 -52 -67 -71 -81 -102 -106 -110 -114 -117 -105 -113 -121 -131 -168 -188 -203 -220
Change (%) 7.87 5.36 -12.65 28.47 6.48 14.13 25.59 3.75 3.73 3.38 3.26 -10.66 7.56 7.11 8.54 28.32 11.56 8.24 8.36
% of Revenue -316.08 -416.28 -494.32 -226.49 -394.78 -395.46 -471.77 -3,600.11 -5,373.66 -3,516.52 -5,151.54 -5,140.26 -477.22 -544.65 -591.10 -649.02 -990,447.06 -507,678.38 -884,026.09 -667,654.55
Interest Expense
Change (%)
% of Revenue
Net Income -52 -57 -60 -52 -67 -71 -81 -102 -105 -107 -110 -111 -96 -101 -105 -110 -143 -161 -176 -196
Change (%) 8.48 5.73 -12.62 27.51 6.79 13.93 25.23 3.39 2.18 2.18 1.39 -13.86 5.11 3.69 5.10 30.56 12.12 9.68 11.17
% of Revenue -314.47 -416.49 -496.31 -227.48 -393.55 -395.37 -470.82 -3,582.61 -5,329.18 -3,435.41 -4,974.55 -4,873.87 -436.28 -486.59 -511.20 -543.54 -844,000.00 -434,778.38 -767,126.09 -594,375.76

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista